A 2026 retrospective longitudinal study published in Frontiers in Neurology investigated the effect of Hyperbaric Oxygen Therapy (HBOT) on sleep quality across three patient populations: healthy aging, long COVID, and PTSD.
The research found that a standard protocol of 60 HBOT sessions was associated with significant, clinically meaningful improvements in overall sleep quality for all groups, with the most substantial benefits observed in patients who had poorer sleep at baseline.
This finding is critically important given that chronic sleep deprivation and poor sleep quality are pervasive public health issues, contributing directly to the progression of numerous diseases, including cognitive decline, cardiovascular disease, metabolic disorders like diabetes, and weakened immune function. In our modern society, where stress, artificial light, and irregular schedules commonly disrupt natural sleep patterns, the resulting “sleep debt” acts as a silent accelerant for chronic illness and reduces overall resilience, making the search for effective, non-pharmacological interventions like HBOT a high clinical priority.
Here are the key findings and their relevance include:
- Overall Improvement: Total Pittsburgh Sleep Quality Index (PSQI) scores improved significantly across all patient groups following HBOT treatment. This suggests HBOT may offer a broad therapeutic tool against the widespread societal burden of inadequate sleep.
- Greatest Benefit for Disturbed Sleep: Patients who started with clinically disturbed sleep (PSQI > 5) experienced broad and significant gains. This is highly relevant as it targets the individuals most at risk for the negative health consequences of poor sleep, potentially interrupting a key factor in disease progression.
- Specific Sleep Components: Significant post-treatment improvements were seen in subjective sleep quality, sleep latency, and sleep disturbances—core issues that degrade daily functioning and long-term health in the general population.
- Condition-Specific Results: Daytime dysfunction improved in the healthy aging and long COVID groups, but not in PTSD. This highlights how sleep interventions can have varying impacts on the functional impairments that drive disability in different conditions.
- Predictor of Success: A higher baseline PSQI score (worse initial sleep) was the strongest predictor of greater improvement after HBOT, allowing for better patient selection and efficient use of clinical resources.
- No Change in Medication: The therapy was not associated with any change in sleep medication use, indicating it may provide benefit without the risks of dependence or side effects associated with pharmacologic sleep aids.
The study concludes that HBOT shows promise as a sleep-modulating therapy, particularly for individuals with existing sleep disturbances—a group for whom improving sleep is not just about rest but a crucial modifiable factor in slowing disease progression and improving health outcomes. It calls for controlled trials to further identify optimal candidates and understand the underlying mechanisms <view study>